Does CAPMATINIB Cause Skin hypertrophy? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Skin hypertrophy have been filed in association with CAPMATINIB (TABRECTA). This represents 0.6% of all adverse event reports for CAPMATINIB.
14
Reports of Skin hypertrophy with CAPMATINIB
0.6%
of all CAPMATINIB reports
0
Deaths
9
Hospitalizations
How Dangerous Is Skin hypertrophy From CAPMATINIB?
Of the 14 reports, 9 (64.3%) required hospitalization.
Is Skin hypertrophy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CAPMATINIB. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does CAPMATINIB Cause?
Death (411)
Peripheral swelling (283)
Fatigue (257)
Oedema peripheral (247)
Nausea (240)
Malignant neoplasm progression (178)
Dyspnoea (141)
Oedema (130)
Asthenia (113)
Non-small cell lung cancer (96)
What Other Drugs Cause Skin hypertrophy?
DUPILUMAB (149)
SECUKINUMAB (134)
ADALIMUMAB (105)
ETANERCEPT (48)
METHOTREXATE (42)
RITUXIMAB (41)
TACROLIMUS (40)
OMALIZUMAB (35)
PREDNISOLONE (35)
SUNITINIB MALATE (32)
Which CAPMATINIB Alternatives Have Lower Skin hypertrophy Risk?
CAPMATINIB vs CAPREOMYCIN
CAPMATINIB vs CAPSAICIN
CAPMATINIB vs CAPTOPRIL
CAPMATINIB vs CARBAMAZEPINE
CAPMATINIB vs CARBETOCIN